Global Microscopic Polyangiitis Treatment Market Outlook 2021: Global Opportunity and Demand Analysis, Market Forecast, 2022-2030

The global Microscopic Polyangiitis (MPA) Treatment market size is projected to reach a CAGR of 7.5% during 20202028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Microscopic Polyangiitis (MPA) Treatment market to help players achieve a strong market position.
The rising development of new MPA treatments, as well as a robust pipeline of pipeline drugs, are the primary drivers.
The global microscopic polyangiitis (MPA) treatment market growth is majorly driven by the rising development of new treatments for MPA and robust pipeline drugs. Some of the pipeline drugs for the treatment of microscopic polyangiitis are Abatacept and IFX 1. Among other things, FDA approval for conducting phase II clinical trials of IFX-1 for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis indicates that the patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes the C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatments for MPA is expected to boost the growth of the microscopic polyangiitis market over the forecast period.
The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare Products Regulatory Agency (MHRA), among others, for several drugs for the treatment of MPA is further driving the growth of the market.
Rituximab Will Play a Significant Role in the Growth of the Global Microscopic Polyangiitis Treatment Market
The treatment of microscopic polyangiitis is predicated on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids like prednisone, utilized in combination with other medications that suppress the system and reduce inflammation. However, even with treatment, MPA may be a chronic condition with periods of relapse and remission, so ongoing medical aid and monitoring are necessary. A number of the drugs available for the treatment of MPA include Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, et al. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab for the treatment of MPA and GPA. (Biologic medications are complex proteins derived from living organisms. They aim at certain parts of the system to regulate inflammation. Rituximab is predicted to realize the maximum share over the forecast period 20202028.

On the other hand, cyclophosphamide is growing at a high rate of growth over the forecast period. Its a chemotherapy-type drug that blocks the abnormal growth of certain cells within the body when taken together with prednisone. Prednisone is usually started at a high dose and tapered off slowly. Cyclophosphamide lowers the bodys ability to fight infection, hence it is usually limited to a three-to six-month period and replaced by less toxic medications like mycophenolate mofetil, azathioprine, or methotrexate, a drug that commonly wont treat atrophic arthritis. Some milder sorts of MPA are typically treated with a mixture of prednisone and methotrexate.
North America is dominated by witnessing the fastest growth in the global microscopic polyangiitis treatment market.
The North American region is dominating the worldwide microscopic polyangiitis (MPA) treatment market, accounting for the utmost market share in 2019, thanks to the increasing development of medicine for the treatment of MPA. Within us, the annual incidence of microscopic polyangiitis is 3.6 cases per million people, and therefore the prevalence is one to three cases per 100,000 people. In September 2019, Roche received U.S. Food and Drug Administration (FDA) approval for Rituxan (rituximab), together with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age or older.

On the other hand, the European microscopic polyangiitis market is projected to grow at a high CAGR over the forecast period thanks to increasing clinical trials and approval of the medicine. As an example, Bristol-Myers Squibb Company is conducting phase III clinical trials for Abatacept (Orencia), which is predicted to be completed by September 2022. Orencia may be a recombinant protein that inhibits the T cell activation pathway, thereby suppressing the system.
Players to Focus on Microscopic Polyangiitis Treatment Market
The microscopic polyangiitis (MPA) treatment market is very competitive and consists of several major players, with the emergence of the latest players within the market. A number of the key players that are contributing to the expansion of the market are
ChemoCentryx Inc.,
Celltrion, Inc.,
Teijin Pharma Ltd,
Sandoz International GmbH (Novartis Division),
TTY Biopharm Company Ltd,
Genentech, Inc.,
InflaRx N.V.,
Bristol-Myers Squibb Company,
Amerigen Pharmaceuticals Limited,

The main players are adopting several growth strategies like product launches, clinical trials, acquisitions, and collaborations, which are contributing to the expansion of the microscopic polyangiitis (MPA) treatment market globally.
Teva Pharmaceutical Industries, an Israeli generics company, and Celltrion, a South Korean biotechnology company, launched their rituximab biosimilar Truxima (TL011) in the United States on May 4, 2020. Truxima (rituximab-abbs) is now available within the US for the treatment of patients with non-Hodgkins lymphoma (NHL), chronic lymphocytic leukemia (CLL), atrophic arthritis, granulomatosis with polyangiitis (Wegeners granulomatosis), and microscopic polyangiitis.
In January 2020, Pfizer announced it would introduce three new biosimilars this year. The company plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr); Rituxan biosimilar Ruxience (rituximab-pvvr); and Herceptin biosimilar Trazimera (trastuzumab-qyyp). Ruxience is approved for the treatment of adult patients with non-Hodgkins lymphoma, chronic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Scope of the Report

By Type
Avacopan
Immune Globulin
Rituximab Biosimilar

By Application
Hospital
Clinic

By Region
North America
Europe
Asia Pacific
Rest Of World


Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders a definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.

Chapter 1 Overview And Scope
1.1 Market Vision
1.1.1 Market Definition
1.1.2 Market Scope
1.2 Market Segmentation

Chapter 2 Our Research Practice
2.1 Our Research Methodology
2.2 Data Triangulation
2.3 Data Sources
2.4 Assumptions for the study
2.5 Approach Adopted

Chapter 3 Executive Summary
3.1 Market Snapshot
3.2 Regional Snapshot
3.3 Segment Summary

Chapter 4 Covid-19 Impact Analysis
4.1 Overview
4.2 Prevalence analysis
4.3 Key Factor Impact Analysis

Chapter 5 Global Microscopic Polyangiitis Treatment Market Forces
5.1 Whats Driving the Market
5.2 Porters Five Forces Analysis
5.2.1 Power of Suppliers
5.2.2 Threats From New Entrants
5.2.3 Power of Buyer
5.2.4 Threat From Substitute Product
5.2.5 Degree of Competition

Chapter 6 Global Microscopic Polyangiitis Treatment Market -Industry Snapshots
6.1 Overview
6.1.1 Global Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
6.2 Market Overview
6.2.1 Drivers Analysis
6.2.2 Restraint/Challenges analysis
6.2.3 Opportunity Analysis
6.3 Supply Chain/Value Chain Analysis
6.4 Market SWOT Analysis

Chapter 7 Global Microscopic Polyangiitis Treatment Market Analysis, by Type
7.1 Overview
7.2 Key Findings for Microscopic Polyangiitis Treatment Market- By Type
7.2.1 Microscopic Polyangiitis Treatment Market- Avacopan
Microscopic Polyangiitis Treatment market by Type 1, 2019 - 2028 (USD Million)
7.2.2 Microscopic Polyangiitis Treatment Market- Immune Globulin
Microscopic Polyangiitis Treatment market by Type 2, 2019 - 2028 (USD Million)
7.2.3 Microscopic Polyangiitis Treatment Market- Rituximab Biosimila

Chapter 8 Global Microscopic Polyangiitis Treatment Market Analysis, by Application
8.1 Overview
8.2 Key Findings for Microscopic Polyangiitis Treatment Market- By Product Type
8.2.1 Microscopic Polyangiitis Treatment Market- Hospital
8.2.2 Microscopic Polyangiitis Treatment Market- Clinic

Chapter 9 Microscopic Polyangiitis Treatment Market Analysis by Region
9.1 Key Findings for Microscopic Polyangiitis Treatment Market- By region
9.2 Overview
9.2.1 Global Microscopic Polyangiitis Treatment Market Analysis, By Type, 2019 - 2028
9.2.2 Global Microscopic Polyangiitis Treatment Market Analysis, By Product Type, 2019 - 2028
9.3 Microscopic Polyangiitis Treatment Market North America
9.3.1 Overview
9.3.2 U.S.
9.3.3 Canada
9.3.4 Mexico
9.3.5 North America Market, By Type
9.3.6 North America Market, By Product Type
9.4 Microscopic Polyangiitis Treatment Market Europe
9.4.1 Overview
9.4.2 Germany
9.4.3 United Kingdom
9.4.4 France
9.4.5 Italy
9.4.6 Rest Of Europe
9.4.7 Europe Market, By Type
9.4.8 Europe Market, By Product Type
9.5 Microscopic Polyangiitis Treatment Market Asia Pacific
9.5.1 Overview
9.5.2 China
9.5.3 Japan
9.5.4 India
9.5.5 Rest of APAC
9.5.6 Asia Pacific Market, By Type
9.5.7 Asia Pacific Market, By Product Type
9.6 Microscopic Polyangiitis Treatment Market Rest Of World
9.6.1 Overview
9.6.2 Middle East & Africa (MEA)
9.6.3 South America
9.6.4 Rest Of World
9.6.5 South America, Middle East and Africa Market, By Type
9.6.6 South America, Middle East and Africa Market, By Product Type

Chapter 10 Market Competition Analysis
10.1 Market Share/Positioning Analysis
10.1.1 Market Positioning of Key Vendors, 2019
10.1.2 Key Strategies Adopted by the Leading Players
10.1.3 Recent Developments

Chapter 11 Company Profiles- Snapshot
11.1 ChemoCentryx Inc.,
11.1.1 Business Fundamentals
11.1.2 Financial Snapshots
11.1.3 Product Portfolio
11.1.4 Recent Developments
11.2 Celltrion, Inc.,
11.3 Teijin Pharma Ltd,
11.4 Sandoz International GmbH (Novartis Division),
11.5 TTY Biopharm Company Ltd,
11.6 Genentech, Inc.,
11.7 InflaRx N.V.,
11.8 Bristol-Myers Squibb Company,
11.9 Amerigen Pharmaceuticals Limited,
*More than 10 Companies are profiled in this Research Report*
*Financials would be provided on a best efforts basis for private companies

Chapter 12 Appendix

List Of Tables

TABLE 1 Microscopic Polyangiitis Treatment market by Type 3, 2019 - 2028 (USD Million)
TABLE 2 Microscopic Polyangiitis Treatment market by Product Type 1, 2019 - 2028 (USD Million)
TABLE 3 Microscopic Polyangiitis Treatment market by Application 2, 2019 - 2028 (USD Million)
TABLE 4 Global Microscopic Polyangiitis Treatment Market Value, By Type, 2019 - 2028 (US$ Bn)
TABLE 5 Global Microscopic Polyangiitis Treatment Market Value, By Product Type, 2019 - 2028 (US$ Bn)
TABLE 6 Microscopic Polyangiitis Treatment Market Analysis by North America (USD Million), 2019 - 2028
TABLE 7 U.S. Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 8 U.S. Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 9 U.S. Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 10 Canada Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 11 Canada Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 12 Canada Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 13 Mexico Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 14 Mexico Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 15 Mexico Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 16 Microscopic Polyangiitis Treatment Market Analysis by Europe (USD Million), 2019 - 2028
TABLE 17 Germany Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 18 Germany Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 19 Germany Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 20 United Kingdom Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 21 United Kingdom Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 22 United Kingdom Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 23 France Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 24 France Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 25 France Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 26 Italy Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 27 Italy Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 28 Italy Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 29 Rest Of Europe Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 30 Rest Of Europe Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 31 Rest Of Europe Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 32 Microscopic Polyangiitis Treatment Market Analysis by Asia Pacific (USD Million), 2019 - 2028
TABLE 33 China Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 34 China Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 35 China Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 36 Japan Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 37 Japan Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 38 Japan Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 39 India Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 40 India Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 41 India Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 42 Rest of APAC Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 43 Rest of APAC Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 44 Rest of APAC Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 45 Microscopic Polyangiitis Treatment Market Analysis by Rest Of World (USD Million), 2019 - 2028
TABLE 46 Middle East & Africa (MEA) Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 47 Middle East & Africa (MEA) Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 48 Middle East & Africa (MEA) Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 49 South America Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 50 South America Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 51 South America Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 52 Rest Of World Microscopic Polyangiitis Treatment Market, 2019 - 2028 (USD Million)
TABLE 53 Rest Of World Microscopic Polyangiitis Treatment Market, By Type, 2019 - 2028 (USD Million)
TABLE 54 Rest Of World Microscopic Polyangiitis Treatment Market, By Product Type, 2019 - 2028 (USD Million)

List Of Figures

FIG. 1 Global Microscopic Polyangiitis Treatment : Market Segmentation
FIG. 2 Global Microscopic Polyangiitis Treatment Market: Research Methodology
FIG. 3 Top-Down and Bottom Up Approach
FIG. 4 Market Snapshot
FIG. 5 Porters Five Forces Analysis
FIG. 6 Global Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
FIG. 7 Supply Chain/Value Chain Analysis
FIG. 8 Global Microscopic Polyangiitis Treatment Market Value Contribution, By Type, 2019 & 2026 (%)
FIG. 9 Global Microscopic Polyangiitis Treatment Market Value Contribution, By Product Type, 2019 & 2026 (%)
FIG. 10 Global Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
FIG. 11 North America Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
FIG. 12 Microscopic Polyangiitis Treatment Market Segment 1 North America
FIG. 13 Microscopic Polyangiitis Treatment Market Segment 2 North America
FIG. 14 Microscopic Polyangiitis Treatment U.S. outlook, 2019 & 2026
FIG. 15 Microscopic Polyangiitis Treatment Canada outlook, 2019 & 2026
FIG. 16 Microscopic Polyangiitis Treatment Mexico outlook, 2019 & 2026
FIG. 17 Europe Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
FIG. 18 Microscopic Polyangiitis Treatment Market Segment 1 Europe
FIG. 19 Microscopic Polyangiitis Treatment Market Segment 2 Europe
FIG. 20 Microscopic Polyangiitis Treatment Germany outlook, 2019 & 2026
FIG. 21 Microscopic Polyangiitis Treatment United Kingdom outlook, 2019 & 2026
FIG. 22 Microscopic Polyangiitis Treatment France outlook, 2019 & 2026
FIG. 23 Microscopic Polyangiitis Treatment Italy outlook, 2019 & 2026
FIG. 24 Microscopic Polyangiitis Treatment Rest Of Europe outlook, 2019 & 2026
FIG. 25 Asia Pacific Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
FIG. 26 Microscopic Polyangiitis Treatment Market Segment 1 Asia Pacific
FIG. 27 Microscopic Polyangiitis Treatment Market Segment 2 Asia Pacific
FIG. 28 Microscopic Polyangiitis Treatment China outlook, 2019 & 2026
FIG. 29 Microscopic Polyangiitis Treatment Japan outlook, 2019 & 2026
FIG. 30 Microscopic Polyangiitis Treatment India outlook, 2019 & 2026
FIG. 31 Microscopic Polyangiitis Treatment Rest of APAC outlook, 2019 & 2026
FIG. 32 Rest Of World Microscopic Polyangiitis Treatment Market Value, 2019 - 2028, (US$ Bn)
FIG. 33 Microscopic Polyangiitis Treatment Market Segment 1 Rest Of World
FIG. 34 Microscopic Polyangiitis Treatment Market Segment 2 Rest Of World
FIG. 35 Microscopic Polyangiitis Treatment Middle East & Africa (MEA) outlook, 2019 & 2026
FIG. 36 Microscopic Polyangiitis Treatment South America outlook, 2019 & 2026
FIG. 37 Microscopic Polyangiitis Treatment Rest Of World outlook, 2019 & 2026


Companies Mentioned

Celltrion Inc
ChemoCentryx Inc
Sandoz International GmbH
Teijin Pharma Ltd
TTY Biopharm Company Ltd

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available